By Adria Calatayud

PureTech Health PLC (PRTC.LN) said Thursday that it has cut its stake in Boston-based Karuna Therapeutics Inc. (KRTX) to 20.4%, raising $200 million in cash.

PureTech, a Boston-based, London-listed biotechnology company, said it sold 2.1 million Karuna shares to Goldman Sachs Group Inc. (GS), after which it continues to hold 5.3 million shares in the Nasdaq-listed company. PureTech continues to have a right to royalty payments on net sales of any commercialized product covered by a license granted to Karuna, it said.

PureTech said the sale provides it with additional cash to fund its growth.

PureTech shares at 0906 GMT were down 1% at 290 pence.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

January 23, 2020 04:27 ET (09:27 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Puretech Health.
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Puretech Health.